Early observations and pilot data that first suggested a new direction
For decades, moderate-to-severe psoriasis was managed with broad immunosuppressants like methotrexate and cyclosporine, which offered modest efficacy at the cost of significant organ toxicity. The recognition that psoriasis was driven by T-cell-mediated inflammation opened the door to targeted biologics. The first anti-TNF-alpha agents, etanercept and infliximab, demonstrated in landmark trials that selective cytokine blockade could achieve PASI 75 responses in 40-80% of patients, fundamentally redefining treatment expectations. These early signals proved that near-complete skin clearance was an achievable therapeutic goal rather than an aspiration.
Landmark RCTs and pivotal trials that established the evidence base
The anti-TNF era matured with adalimumab's REVEAL trial demonstrating PASI 75 in 71% of patients at week 16, establishing it as the market-leading biologic for psoriasis. Simultaneously, ustekinumab targeting IL-12/23 in the PHOENIX 1 and PHOENIX 2 trials showed that upstream cytokine blockade could achieve durable responses with less frequent dosing. These large, well-powered phase III programs confirmed that biologics were not just effective but transformatively so, with safety profiles favorable compared to traditional systemic agents. The PASI 75 benchmark became the new minimum standard for regulatory approval.
Follow-up studies, subgroup analyses, and real-world validation
The IL-17 inhibitors secukinumab and ixekizumab raised the bar dramatically, with the ERASURE and FIXTURE trials showing PASI 90 rates of 60-70% — making near-complete clearance the new treatment target. The subsequent IL-23 inhibitors guselkumab (VOYAGE 1/2) and risankizumab (ULTIMMA 1/2) achieved similar or superior PASI 90/100 rates with even less frequent dosing, sometimes as infrequently as every 12 weeks after loading. Head-to-head trials like IXORA-S and ECLIPSE demonstrated the superiority of IL-17 and IL-23 agents over older biologics, reshaping treatment algorithms. The therapeutic goal shifted from PASI 75 to PASI 90 or even PASI 100 — complete clearance — as a realistic primary endpoint.
Integration into clinical practice guidelines and recommendations
Current guidelines from the AAD, BAD, and European consensus position biologics as first-line systemic therapy for moderate-to-severe psoriasis, with IL-17 and IL-23 inhibitors preferred over anti-TNF agents based on superior efficacy in head-to-head trials. The AAD-NPF 2020 guidelines recommend a treat-to-target approach with PASI 90 or BSA ≤3% as the treatment goal. NICE and European guidelines similarly emphasize early biologic initiation rather than sequential failure through conventional systemics. Comorbidity screening (cardiovascular, metabolic, psychiatric) is universally recommended given psoriasis as a systemic inflammatory disease.
AAD-NPF Joint Guidelines for Management of Psoriasis with Biologics
Biologics recommended as first-line systemic therapy for moderate-to-severe psoriasis; IL-17 and IL-23 inhibitors preferred based on efficacy data
British Association of Dermatologists (BAD) Guidelines
Biologic therapy recommended when conventional systemics fail or are contraindicated; treat-to-target approach endorsed
European Consensus on Psoriasis Treatment Goals
PASI 90 or absolute PASI ≤2 at 6 months as primary treatment target
Now
Current standard of care and ongoing research directions
The psoriasis treatment landscape in 2025-2026 features over a dozen approved biologics across four mechanism classes, with IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) and IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab) dominating new prescriptions. Oral small molecules like deucravacitinib (TYK2 inhibitor) offer a non-injectable alternative. Complete clearance (PASI 100) is achievable in 30-60% of patients with modern agents. Research frontiers include personalized biomarker-guided therapy selection, sustained drug-free remission strategies, and expansion into psoriatic arthritis co-management with single-agent biologics.
Why have IL-23 inhibitors become preferred over anti-TNF agents?+
IL-23 inhibitors achieve higher PASI 90/100 rates (60-75%) with less frequent dosing (every 8-12 weeks after loading) compared to anti-TNF agents (PASI 90 rates 30-50%). Head-to-head trials consistently demonstrate superiority, and the narrower immunological target may offer better long-term safety.
Is PASI 100 (complete clearance) a realistic treatment goal?+
Yes. With IL-23 inhibitors like risankizumab, PASI 100 is achieved in 35-55% of patients by week 52. This has shifted the treatment paradigm from 'improvement' to 'clearance' as the standard aspiration.
How do biologics compare to methotrexate for psoriasis?+
The CHAMPION trial showed adalimumab achieved PASI 75 in 80% vs 36% for methotrexate at week 16. Modern IL-17/IL-23 agents are even more effective. However, methotrexate remains useful as combination therapy and in resource-limited settings at a fraction of biologic cost.
What is the role of biosimilars in psoriasis treatment?+
Multiple adalimumab, etanercept, and infliximab biosimilars are now available, reducing costs by 30-80%. While uptake varies by region, biosimilars have expanded access particularly in public health systems and are considered therapeutically equivalent by all major guidelines.
